CD207 CAR-T cells

CD207 CAR-T cells are a form of chimeric antigen receptor T cell therapy in which autologous or allogeneic T lymphocytes are genetically engineered to express a synthetic receptor targeting the CD207 antigen (also known as Langerin, encoded by CLEC4K). This modification enables the T cells to specifically recognize and kill malignant or pathogenic cells expressing CD207. The primary indication for this therapy is relapsed and refractory Langerhans cell histiocytosis (LCH), a rare hematologic malignancy characterized by proliferation of Langerhans-type dendritic cells. The mechanism of action involves direct cytotoxicity against CD207-expressing target cells through immune-mediated killing. As of 2025, development is led by Beijing Friendship Hospital, with clinical trials ongoing at Phase 1[1][2].